Studies conducted on mouse models of AD have shown that in animals with mild tau pathology, it was possible to reverse it with a simultaneous decline in cognitive functions by intravenous administration of a selective A1 receptor antagonist (rolofylline). The gene discussed is MAPT; the disease is Alzheimer disease.